Joe Jimenez (Steffen Schmidt/Keystone via AP,file)
November 7, 2024 07:03 AM EST
Startups
Deals
China

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

Kyle LaHucik

Senior Reporter

Joe Jimenez’s Adi­tum Bio, an in­vest­ment firm that builds com­pa­nies around in-li­censed as­sets, is go­ing af­ter one of the hottest new ar­eas for its lat­est …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times